Astrocytes modulate neuronal activity, synaptic transmission, and behavior by releasing chemical transmitters in a process termed gliotransmission. Whether this process impacts epilepsy in vivo is not known. We show that genetic impairment of transmitter release from astrocytes by the expression of a glial dominantnegative SNARE domain in mice reduced epileptiform activity in situ, delayed seizure onset after pilocarpine-induced status epilepticus, and attenuated subsequent progressive increase in seizure frequency in vivo. The reduced seizure frequency was accompanied by attenuation of hippocampal damage and behavioral deficits. As the delay in seizure onset and the reduced seizure frequency were mimicked by intracerebroventricular delivery of the NMDA receptor (NMDAR) antagonist D-(-)-2-amino-5-phosphonopentanoate in WT littermates and because dominant-negative SNARE expression leads to a hypofunction of synaptic NMDARs, we conclude that astrocytes modulate epileptogenesis, recurrent spontaneous seizures, and pathophysiological consequences of epilepsy through a pathway involving NMDARs.
Astrocytes modulate neuronal activity, synaptic transmission, and behavior by releasing chemical transmitters in a process termed gliotransmission. Whether this process impacts epilepsy in vivo is not known. We show that genetic impairment of transmitter release from astrocytes by the expression of a glial dominantnegative SNARE domain in mice reduced epileptiform activity in situ, delayed seizure onset after pilocarpine-induced status epilepticus, and attenuated subsequent progressive increase in seizure frequency in vivo. The reduced seizure frequency was accompanied by attenuation of hippocampal damage and behavioral deficits. As the delay in seizure onset and the reduced seizure frequency were mimicked by intracerebroventricular delivery of the NMDA receptor (NMDAR) antagonist D-(-)-2-amino-5-phosphonopentanoate in WT littermates and because dominant-negative SNARE expression leads to a hypofunction of synaptic NMDARs, we conclude that astrocytes modulate epileptogenesis, recurrent spontaneous seizures, and pathophysiological consequences of epilepsy through a pathway involving NMDARs.
glia-to-neuron signaling | pilocarpine mouse | electroencephalography | hippocampus | interictal spikes T emporal lobe epilepsy (TLE), one of the most common neurological disorders, which affects 1% of the population worldwide, is characterized by the occurrence of recurring unprovoked spontaneous seizures. Unfortunately, seizures in 30% of patients with TLE are not controlled by anticonvulsant agents, drugs that are directed to neuronal targets. In this case, patients may undergo resective epilepsy surgery to become seizure-free (1) .
Emerging evidence suggests a critical role for the glial cells, astrocytes, in epilepsy (2, 3) . Astrocytes play an important role in maintaining central nervous system function by releasing gliotransmitters, including glutamate, D-serine, and ATP (4) . Whether gliotransmission contributes to epilepsy in vivo has not been established. It has recently been shown that gliotransmission regulates the trafficking and surface expression of the neuronal N-methyl-D-aspartate receptor (NMDAR) subunits 2A and 2B (5, 6) . Because of the importance of NMDARs in epilepsy (7), we hypothesize that astrocytes modulate epileptic seizures by regulating these receptors. To test this hypothesis, we used astrocytespecific molecular genetics in mice to inhibit transmitter release from astrocytes, along with the in vivo pilocarpine model of TLE, long-term continuous video EEG, and an in situ hippocampal slice model of epilepsy.
We show that genetic impairment of transmitter release from astrocytes by the expression of glial dominant-negative SNARE (dnSNARE) (8) delayed the onset of spontaneous recurrent seizures (SRSs) and attenuated the progressive increase in frequency of SRSs, hippocampal sclerosis, and the appearance of aberrant open-field behaviors. Similarly, chemically induced epileptiform activity in situ was attenuated by the expression of astrocytic dnSNARE. The ability of dnSNARE to reduce epileptiform activity in situ and seizure frequency in vivo was phenocopied by antagonism of the NMDAR with D-(-)-2-amino-5-phosphonopentanoate (D-AP5), indicating that astrocytic signals contribute to the progressive development of epilepsy through the modulation of neuronal NMDAR activity.
Results
Pilocarpine-Induced Status Epilepticus Is Comparable in WT and dnSNARE Mice. To determine contributions of astrocytes to epileptogenesis, we used the pilocarpine model of epilepsy in mice, a model known to be highly isomorphic with human TLE (9) , and asked whether the expression of dnSNARE in astrocytes modulated the development of SRSs. Repeated low doses of pilocarpine (100 mg/kg) were injected i.p. until the onset of status epilepticus (SE; Fig. S1A ). This ramping protocol has been shown to reduce mortality after SE (10) . No differences in the behavioral seizure score were seen between dnSNARE animals and their WT littermates ( Fig. S1 A-C). EEG recordings also showed that electrographic features of acute seizures and SE were similar between WT and dnSNARE mice (Fig. S1 D 
-K).
These data indicate that astrocytic dnSNARE expression does not alter the acute responses to pilocarpine.
Astrocytic dnSNARE Expression Attenuates the Progressive Development
of SRSs. To determine whether astrocytic dnSNARE expression impacts the development of epilepsy, we performed continuous video EEG recordings that commenced 5 d after SE and continued for as long as 150 d. The latency from SE to onset of the first SRS was significantly lengthened in dnSNARE mice compared with WT mice (latency to seizure onset in WT mice, 13 .33 ± 0.55 d vs. 17 .00 ± 1.34 d in dnSNARE mice; n = 6 per genotype; Student t test, P < 0.05, Fig. 1A ). All mice that experienced SE subsequently exhibited interictal spikes, hallmarks of the epileptic brain (11) , and developed epilepsy with more than Significance Temporal lobe epilepsy (TLE) is a chronic brain disorder characterized by the occurrence of spontaneous recurrent seizures. Much of our knowledge of epilepsy is based on how neurons contribute to this disorder. Here we provide a view in which glial cells (astrocytes) contribute to the progressive development of TLE. We have combined a model of epilepsy that more closely mimics the complex features of seizures in epileptic patients, with astrocyte-specific molecular genetics to identify how astrocytes modulate the progressive development of TLE, including seizure occurrence, brain damage, and behavioral deficits. We provide evidence of the glial regulation of neuronal NMDA receptors in this process. This study identifies astrocytes as a potential therapeutic target for the treatment of epilepsy.
two SRSs (Fig. 1B) . In both genotypes, each seizure was characterized by a typical increase in β-band power (13-30 Hz; Fig. S2 ). Control mice that had been injected with pilocarpine but did not enter SE displayed a normal EEG dominated by δ-band power (1-4 Hz; Fig. S2 ), with neither interictal spikes nor seizures (Fig.  1B) . Additionally, the delayed seizure onset in dnSNARE mice was accompanied by a significant reduction in the number of interictal spikes ( Fig. 1 C and D) .
Continuous video EEG monitoring showed that SRSs occurred in clusters in both genotypes (Fig. 1E) , a distinct feature of the pilocarpine model (12) . During the first month after SE, there was no difference in initial seizure frequency between WT and dnSNARE mice (Fig. 1F) . The frequency of SRSs increased progressively over time in WT mice, from 0.40 ± 0.10 seizures per day (1 mo after SE; n = 6) to 1.94 ± 0.65 seizures per day (5 mo after SE; n = 6; Mann-Whitney test, P < 0.01; Fig. 1 E and F and Fig. S3A ), whereas it remained unchanged in dnSNARE mice (1 mo after SE, 0.48 ± 0.10 seizures per day vs. 0.66 ± 0.19 seizures per day at 5 mo after SE; n = 8 for both conditions; Student t test, P > 0.05; Fig. 1 E and F and Fig. S3A ). The initial frequency of SRSs in WT mice at 1 mo after SE predicted the elevated frequency of SRSs 4 mo later (linear regression, y = 6.96x -0.31, r 2 = 0.7559, n = 5; Fig. S3B ) whereas, in dnSNARE mice, seizure frequency remained constant throughout this period (linear regression: y = −0.03x + 0.68, r 2 = 0.0005, n = 8; Fig.  S3B ). Whereas the severity of SRSs was reduced in dnSNARE mice compared with WT mice during the first 2 mo after SE (Fig.  1G) , the duration of individual seizures remained similar over time (Fig. S3C) . Additionally, the number of interictal spikes per day in WT mice increased progressively over time after SE (Fig.  S3D) , as described in another animal model of epilepsy (11) . The average number of interictal spikes per day during the entire period of EEG recording was significantly reduced in dnSNARE mice compared with WT mice [WT mice, 9,614.88 ± 2,223.78 interictal spikes per day (n = 5), vs. 3,228.46 ± 629.44 interictal spikes per day in dnSNARE mice (n = 7); Mann-Whitney test, P < 0.05; Fig. S3D ]. These results suggest that astrocytic dnSNARE expression prevents the progressive increase in seizure frequency and reduces interictal spiking during the chronic phase of epilepsy.
Astrocytic dnSNARE Expression Attenuates Behavioral Deficits During
Epilepsy. In patients and animal models, TLE is associated with long-term behavioral abnormalities (13, 14) . We then asked whether astrocytic dnSNARE expression would attenuate the development of these behavioral defects. To this end, we observed mice in the open field 8 mo after pilocarpine injections to examine gross locomotor activity and explorative habits. Control no-SE WT and dnSNARE mice exhibited the normal pattern of open field behavior that consisted of exploratory paths and stops, primarily in the corners of the arena (Fig. 2 A and B) . SE increased the duration of time stopped in the open field in WT mice ( Fig. 2 A, C, and D) but not in dnSNARE mice (Fig. 2 B, C , and D). In WT and dnSNARE mice, the cumulative distance and speed were not altered by SE (Fig. S4 A and B) . Thus, astrocytic dnSNARE expression prevents the overall changes in the structure of the open-field behavior of epileptic mice.
Astrocytic dnSNARE Expression Reduces Neuronal Loss and Reactive
Astrocytosis During Epilepsy. To evaluate the pathological correlates of seizure development in the pilocarpine model of TLE, we performed immunostaining in the hippocampus of mice 8 mo after pilocarpine treatment. To determine loss of neurons, we performed immunostaining against the neuronal marker NeuN (15) . In WT and dnSNARE mice, SE caused striking neuronal loss in the CA1 and CA3 subfields ( Fig. S5 A and B) . SE also significantly reduced the number of dentate hilar neurons in WT mice but not in dnSNARE mice (Fig. 3A) . We noted that, at 10 mo of age (8 mo after pilocarpine treatment), there was a small decline in dentate hilar neurons in dnSNARE mice compared with WT mice that did not exhibit SE (Fig. 3A) . However, in control experiments at 2 mo of age, dnSNARE mice did not have fewer dentate hilar neurons compared with WT mice (WT mice, 500.81 ± 16.06 neurons per square millimeter, vs. 536.82 ± 37.21 neurons per square millimeter in dnSNARE mice; n = 3 animals for each genotype; Student t test, P > 0.05), suggesting that astrocytic dnSNARE expression does not impact the density of dentate hilar neurons at the age of onset of the study.
To assess reactive astrocytosis, we performed immunostaining against the glial marker GFAP (15) as well as vimentin (16) . SE significantly increased GFAP and vimentin expression in the hippocampus of WT mice (Fig. 3B and Figs. S5 C and D and S6). In contrast, the expression of astrocytic dnSNARE prevented SE-induced reactive astrocytosis (Fig. 3B and Figs. S5 C and D and S6). These results show that astrocytic dnSNARE expression is neuroprotective in the dentate hilus and prevents reactive astrocytosis during epilepsy.
Astrocytic dnSNARE Expression Reduces Epileptiform Activity in Situ
by Reducing NMDAR Activity. To understand the mechanism of astrocytic influence over SRSs, we used an acute slice model of epileptiform activity to ask whether glial control of neuronal NMDARs (5, 6) contributes to the modulation of SRSs. When hippocampal slices were perfused with an artificial cerebrospinal fluid (ACSF) containing 0 Mg 2+ and picrotoxin (100 μM), extracellular recordings in the CA1 region showed typical epileptiform activity characterized by the occurrence of ictal-like events (duration > 2 s; low frequency < 1 event per minute; Fig. 4A ). In agreement with results obtained on SRSs in vivo, slices from dnSNARE animals displayed a significant increase in the latency to onset of epileptiform activity (Fig. 4 A and B) and a significant decrease in the frequency of ictal-like events (Fig. 4 A and C) . Duration of ictal-like events was not altered by the dnSNARE transgene [ictal-like event duration in WT mice, 24.82 ± 9.92 s (n = 5 slices from five animals), vs. 21.32 ± 6.72 s in dnSNARE mice (n = 5 slices from five animals); Student t test, P > 0.05; Fig. 4A ].
Our previous studies have shown that astrocytic dnSNARE expression leads to a reduction in synaptic NMDA currents in the cortex (5, 6) , which is expected to reduce neuronal excitability and could mediate the effects of astrocytic dnSNARE expression on epileptiform activity. We performed patch-clamp recordings from CA1 pyramidal neurons and determined that astrocytic dnSNARE expression increased the AMPA/NMDA ratio at the hippocampal synapses (Fig. 4D) . To determine whether this was caused by a postsynaptic modulation of NMDARs, we recorded mixed AMPA and NMDA miniature excitatory postsynaptic currents (EPSCs; mEPSCs) in ACSF containing 1 μM TTX and 0 Mg 2+ to enhance the NMDA component of mEPSCs (Fig. S7) as described by Deng et al. (6) . By using the NMDAR antagonist D-AP5 (50 μM), we found that the amplitude of mixed mEPSCs 20 ms following the peak was a reliable indicator of the NMDA current contribution (Fig. 4E) . Astrocytic dnSNARE expression significantly decreased the amplitude of synaptic NMDA current by 35% (Fig. 4 E and F) without changing the amplitude of synaptic AMPA current (Fig.  4 E and G) .
To determine whether the reduced epileptiform activity observed in dnSNARE slices could be mimicked by reducing NMDAR activity, we perfused WT slices with 1 μM D-AP5, a concentration that reduced the synaptic NMDA current by 32% (Fig. S8) . Application of 1 μM D-AP5 in WT slices significantly increased the latency to onset of epileptiform activity (Fig.  4 A and B) and significantly decreased the frequency of ictal-like events (Fig. 4 A and C) , mimicking the in situ and in vivo dnSNARE phenotype. In contrast, astrocytic dnSNARE expression occluded the effects of D-AP5 ( Fig. 4 A-C). Thus, these results indicate that the reduced epileptiform activity seen in dnSNARE slices is a consequence of astrocytic dnSNAREdependent hypofunction of NMDARs.
Before asking whether in vivo treatment of WT mice with D-AP5 would phenocopy dnSNARE mice, we determined whether the astrocytic dnSNARE-dependent hypofunction of NMDARs was conserved during epilepsy. The AMPA/NMDA current ratio The average duration of time stopped over the 30-min test period was increased in SE WT mice but not in SE dnSNARE mice (WT no-SE, n = 8; WT SE, n = 7; dnSNARE no-SE, n = 7; dnSNARE SE, n = 8; ANOVA followed by post hoc test, *P < 0.05, WT SE vs. WT no-SE). (D) Line graph shows duration of time stopped in 1-min bins over the 30-min test period. Fig. 3 . Astrocytic dnSNARE expression attenuates hippocampal sclerosis during epilepsy. (A) Representative hippocampal sections from control no-SE and SE-experienced WT and dnSNARE mice stained with an antibody directed against the neuron-specific epitope NeuN 8 mo after pilocarpine treatment. Striking neuronal cell loss was observed in the hilus (h) of the dentate gyrus (DG) in SE WT mice but not in SE dnSNARE mice. Average neuronal density in the hilus of the DG is presented under the corresponding sections (WT no-SE, n = 3 animals; WT SE, n = 7 animals; dnSNARE no-SE, n = 5 animals; dnSNARE SE, n = 4 animals; ANOVA followed by post hoc test, **P < 0.01 and ***P < 0.001; ns, nonsignificant). (B) Same hippocampal sections as in A but stained with an antibody directed against the astrocytespecific epitope GFAP. GFAP expression was increased in the hilus (h) of the DG in SE WT mice but not in SE dnSNARE mice. Average GFAP area in the hilus of the DG is presented under the corresponding sections (ANOVA followed by post hoc test, *P < 0.05; ns, nonsignificant). (Scale bars: 100 μm.) measured in CA1 pyramidal neurons 5 mo after pilocarpine treatment was significantly increased in dnSNARE mice compared with WT mice regardless of whether they had previously exhibited SE ( Fig. 5 A and B) . Pyramidal neurons from mice with SE were filled with biocytin for post hoc cell type identification (Fig. 5B) . Additionally, the dnSNARE transgene did not alter the frequency and amplitude of AMPA receptor (AMPAR)-mediated spontaneous EPSCs (sEPSCs) in mice with or without SE ( Fig. 5 C-F) , indicating that the increased AMPA/NMDA current ratio was not caused by a modulation of AMPARs but rather by a change in NMDAR current. Thus, these data demonstrate that the reduced NMDAR current seen in dnSNARE mice was maintained throughout the period of SRSs.
In Vivo Antagonism of NMDARs Attenuates the Progressive Development of SRSs. We then asked whether in vivo antagonism of NMDAR activity would lead to a long-term reduction in SRSs. To this end, we used osmotic minipump to intracerebroventricularly (i.c.v.) introduce the NMDAR antagonist D-AP5 (or ACSF vehicle) in WT and dnSNARE mice 5 d after SE for 2 wk while continuously recording video EEG for 2 mo ( (Fig. 6 E-G). Thus, these results demonstrate that chronic in vivo antagonism of NMDARs after SE delays seizure onset, reduces seizure severity, and attenuates the progressive increase in seizure frequency, mimicking the dnSNARE phenotype.
Discussion
In summary, we have used genetic, electrophysiological, behavioral, and histological tools to elucidate the role of astrocytes in epilepsy. Our studies demonstrate a major role for astrocytes in the progressive development of SRSs after SE. Genetic impairment of the SNARE complex in astrocytes leads to a hypofunction of postsynaptic NMDARs and ameliorates the development of epilepsy that includes progressive increase in seizure frequency, hippocampal sclerosis, and behavioral abnormalities.
By using the pilocarpine model of TLE along with continuous video EEG, we demonstrate that inhibition of transmitter release from astrocytes lengthens the latent phase of epilepsy, reduces seizure severity, and attenuates the progressive increase in seizure and interictal spike frequency during the chronic phase of epilepsy. As defined by previous studies that showed the importance of chronic video EEG recordings in studies of epilepsy (12, 17, 18) , sustained monitoring was required to reveal the epilepsy phenotype in dnSNARE mice. The progressive nature of epilepsy and the seizure clustering presented here have been described in epileptic patients (19, 20) and various animal models of epilepsy (12, 17, 18) . It is surprising that SE was not affected in dnSNARE mice given that recent in situ studies suggest that astrocytic calcium signals could contribute to the initiation of seizure during SE through a glutamate-mediated mechanism (21) . However, this mechanism operates at the seizure focus by lowering the epileptic threshold and becomes dispensable in the presence of saturating stimuli (21) . It is likely that our pilocarpine treatment is a saturating stimulus that masks this threshold-modulating mechanism.
In accordance with our previous studies showing that dnSNARE expression in astrocytes leads to a reduction in the surface expression of synaptic NMDARs in the cortex (5, 6), we identified a reduced activity of NMDARs at the CA1 hippocampal synapses that persisted during epilepsy. Importantly, chronic i.c.v. administration of D-AP5 following SE in WT animals mimicked the dnSNARE phenotype by increasing the latency to seizure onset, reducing seizure severity and attenuating the progressive increase in seizure frequency over time. Equally important, these seizure-suppressing effects of D-AP5 were occluded following astrocytic dnSNARE expression, confirming that there was a smaller contribution of NMDARs to epilepsy in dnSNARE animals. These results are further supported by the fact that the regulation of NMDAR trafficking directly influences epileptiform discharges in situ (22) and seizure susceptibility in vivo (23) . Interestingly, we found that treatment with D-AP5 during the latent period of epileptogenesis was sufficient to phenocopy the long-term effects of astrocytic dnSNARE expression, suggesting that there is a temporal window during which the reduced activity of NMDARs leads to longterm consequences on epilepsy.
We have previously identified a possible mechanism by which astrocytes control neuronal NMDAR activity (6) . We have shown that astrocytic dnSNARE expression leads to a reduction in synaptically accessible adenosine acting on adenosine A1 receptors 6) . Whether astrocytes use this mechanism to modulate NMDAR activity during epileptic conditions will be investigated in future studies. Several studies have raised the potential for a causal role for astrocytic glutamate in epilepsy (21, 26) , although Fellin et al. (27) describe a different view. It is important to note that these studies were mainly performed in situ and used pharmacological approaches that do not allow the selective manipulation of astrocytic signals. Additionally, the NMDAR coagonist D-serine, released from astrocytes through a SNARE-dependent mechanism (28), could also contribute to our epilepsy phenotype. However, the glutamate and D-serine levels measured with microelectrode biosensors in hippocampal slices were not affected by astrocytic dnSNARE expression (Fig. S9) . Conclusions must be drawn carefully because biosensors measure average signals and they may make such measurements in a different spatial domain than local to the tripartite synapse. However, changes in glutamate and D-serine believed to arise from astrocytes have been previously measured by using biosensors, suggesting that this approach has the appropriate spatiotemporal sensitivity (29, 30) . Consequently, our inability to measure dnSNAREdependent changes in glutamate and D-serine with biosensors makes it unlikely that the nonprogressive development of epilepsy discovered in dnSNARE animals was a consequence of an impaired release of glutamate and/or D-serine from astrocytes.
In agreement with studies showing that experimental and human TLE are associated with behavioral abnormalities (13, 14) , we observed that exploratory behavior of epileptic WT mice was strongly affected in the open field test. Epileptic WT mice presented a striking increase in duration of stops between subsequent locomotor excursions. Interestingly, the dnSNARE transgene strongly attenuated these abnormal behavioral defects. It is important to note that, because of the striking impact of epilepsy in WT mice on open-field behavior, it was not possible to assess other cognitive functions of these mice because impaired locomotor activity in the open field is a significant experimental confound for other tasks (31) . Thus, by comparing WT and dnSNARE mice, we established a link between the degree of behavioral impairment and the severity of hippocampal sclerosis during epilepsy.
In conclusion, by combining a model of epilepsy that more closely mimics the complex features of seizures in epileptic patients with astrocyte-specific molecular genetics, we demonstrate that astrocytes modulate the progressive development of epilepsy in vivo including seizure occurrence, brain damage, and behavioral deficits. We also provide strong evidence of the importance of NMDARs in this process.
Materials and Methods
Animals. The generation of dnSNARE mice has been previously reported (8) . Details are given in SI Materials and Methods.
Pilocarpine-Induced Epilepsy. Male mice (2 mo old) were subjected to pilocarpine treatment to induce SE. Protocols for surgical implantation of cortical EEG electrodes, video EEG monitoring, and scoring of seizure behavior are detailed in SI Materials and Methods.
Behavioral Study. Detailed protocol for the open-field test is given in SI Materials and Methods.
Immunofluorescence Staining. After behavioral study, mice were anesthetized and perfused with paraformaldehyde. Coronal brain sections (40-μm thickness) were immunostained, examined, and analyzed as described in SI Materials and Methods.
Electrophysiology. Acute coronal cortical-hippocampal slices (310-400 μm) were prepared, and extracellular recordings, whole-cell recordings, and data analysis were performed as described in SI Materials and Methods.
In Vivo Pharmacology. Two days after SE, mice were implanted with cortical EEG electrodes and brain cannulas. Osmotic minipumps were filled with D-AP5 (5 mM) or vehicle (ACSF), externalized, and connected to the brain cannula. Details are given in SI Materials and Methods.
Statistical Analysis. Statistical analysis is detailed in SI Materials and Methods.
Significance was set at P < 0.05. Data are shown as mean ± SEM.
Supporting Information
Clasadonte et al. 10 .1073/pnas.1311967110 SI Materials and Methods Animals. We used a line of transgenic mice-dominant-negative SNARE (dnSNARE) mice-in which there is an astrocytespecific expression of an inducible dominant-negative form of synaptobrevin II that inhibits the release of chemical transmitters, including ATP. The generation of the dnSNARE mice has been previously reported (1) . Bigenic GFAP.tTA and tetO.dnSNARE transgenic animals (i.e., dnSNARE mice) and their WT littermates were used. GFAP.tTA mice and tetO.dnSNARE mice were backcrossed at least 10 generations onto the C57BL/6J background before intercrossing. Mice were bred and housed in a room with controlled photoperiods (12 h light and 12 h darkness) and temperature (21-23°C) with food and water ad libitum. WT and dnSNARE mice were fed a diet containing doxycycline (40 mg/kg) from conception until weaning (3 wk of age). All procedures were in strict accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the Tufts University Institutional Animal Care and Use Committee.
Pilocarpine-Induced Epilepsy, Video EEG Monitoring, and Seizure Classification. Adult male dnSNARE and WT mice (2 mo old; weight, >20 g) were used in these experiments. WT and dnSNARE mice were maintained on doxycycline containing food until weaning (postnatal day 21), when they were switched to a regular diet to allow the transgene expression in the dnSNARE animals. Thirty minutes before the injections of pilocarpine, methylscopolamine (a muscarinic antagonist) was administered intraperitoneally (1 mg/kg; Sigma) to reduce adverse, peripheral effects. Then, mice were intraperitoneally injected with repeated low-dose pilocarpine hydrochloride (a muscarinic agonist, 100 mg/kg; Sigma) every 20 min until onset of status epilepticus (SE) characterized by continuous tonic-clonic seizures. Ninety minutes after the onset of SE, diazepam (4 mg/kg; Hospira) was administered s.c. to reduce seizure activity. Mice that did not develop SE after the fourth injection of pilocarpine were used as controls. After SE, all animals were intraperitoneally injected with lactated Ringer solution and fed with soaked rodent food. The seizure severity was scored according to the scale of Racine (2): score 0, no signs of motor seizure activity; score 1, immobility, rigid posture; score 2, repetitive movements, head bobbing; score 3, severe seizures with rearing without falling; score 4, severe seizures with rearing and falling, running and jumping, loss of righting ability; and score 5, SE characterized by continuous tonic-clonic seizures.
The electrographic features of spontaneous recurrent seizures (SRSs) were analyzed with a video EEG monitoring system (Pinnacle Technology). Two days after SE, mice were anesthetized with isoflurane and placed into a stereotaxic frame. Skull surface was exposed, and four insulated wire electrodes (Cooner Wire) were placed and screwed as follows: two extradural cortical electrodes were inserted bilaterally in the frontal areas and the two others were inserted bilaterally in the parietal areas. Electrodes connected to a microconnector (Pinnacle Technology) were secured at the surface of the skull with dental acrylic. After surgery, mice were intraperitoneally injected with buprenorphine (0.08 mg/kg) and lactated Ringer solution, fed with soaked rodent food, and allowed to recover for 3 d before recording. Freely moving mice were placed into individual Plexiglas circle boxes (Pinnacle Technology) and their microconnectors plugged to an EEG preamplifier (Pinnacle Technology). The electrical signal was filtered (pass-band, 1-100 Hz), digitized at 200 Hz, and acquired with a computer-based system (Pinnacle Technology). Mice were considered epileptic when more than two SRSs were observed. To detect seizures, EEG recordings were automatically screened with SleepSign for Animal software on the basis of 4-s epochs and analyzed using a fast Fourier power spectral analysis. Power was analyzed in five frequency bands: δ (1-4 Hz), θ (4-8 Hz), α (8-13 Hz), β (13-30 Hz), and γ (30-40 Hz). An electrographic seizure was characterized by high EEG activity along with a typical increase in the β-band power (Fig. 1B and  Fig. S2 ). The detection of each seizure was visually confirmed by using video recording. EEG interictal spikes were clearly distinguishable from baseline EEG activity by their repetitive occurrence, large amplitude, and sharp morphology (3). In few cases, spikes with amplitudes that saturated the amplifier inputs occurred. They were always associated with movement artifacts and excluded from the analysis. Spike counting was performed with Spike2 software (CED).
To examine the electrographic features of SE, mice were implanted with EEG as described earlier 5 d before induction of SE. In these experiments, SE was induced with a single high dose of pilocarpine hydrochloride (333 mg/kg, i.p.; Sigma).
Open-Field Test. Eight months after injections of pilocarpine, mice implanted with EEG electrodes (SE and control mice) were subjected to the open-field test. Mice were allowed to acclimate to the experimental room for 30 min before behavioral testing. The experiment was performed only if no motor seizure was observed for at least 1 h before the test. Mice were placed individually for 30 min in the center of an opaque-sided box (measuring 44 cm long × 44 cm wide × 44 cm high). A video camera was placed above the open field, and a video tracking system was used to evaluate the exploratory behavior. Before each trial, the field was cleaned thoroughly with 70% (vol/vol) ethanol solution and dried with paper towels. Mice that experienced SRS during a trial were excluded from the analysis.
Immunofluorescence Staining. After completion of the behavioral study, mice were deeply anesthetized with a mixture of ketamine hydrochloride and xylazine hydrochloride. They were perfused sequentially via the left ventricle with 20 mL chilled PBS solution (1×) and 100 mL 4% (wt/vol) paraformaldehyde in PBS solution (1×, pH 7.4). Brains were removed and postfixed in the same fixative for 24 h at 4°C. After fixation, they were soaked 24 h in a solution of 30% (wt/vol) sucrose. Brains were cut serially at 200-μm intervals on a freezing microtome (SM2000R; Leica) into coronal sections at a thickness of 40 μm and then stored in an antifreeze solution at −20°C until immunostaining. Immunostaining was conducted on free-floating sections incubated with 5% (vol/vol) normal goat serum blocking solution for 1 h at room temperature and then with primary antibodies overnight at 4°C on a shaking platform. The following antibodies were used: mouse anti-NeuN (1:1,000; Chemicon), rabbit anti-GFAP (1:1,000; Sigma), and chicken anti-vimentin (1:1,000; Abcam). Sections were rinsed three times with 1× PBS solution and then incubated with secondary antibodies for 2 h at room temperature. The following secondary antibodies were used: goat anti-mouse Alexa 546 (1:1,000; Invitrogen), goat anti-rabbit Alexa 633 (1:1,000; Invitrogen), and goat anti-chicken Alexa 488 (1:1,000; Invitrogen). For biocytin staining, slices were fixed overnight with 4% (wt/vol) paraformaldehyde in PBS solution (1×, pH 7.4) at 4°C, then rinsed several times with PBS solution and incubated with 0.4% Triton X-100/PBS solution and streptavidin Alexa 546 (1:250; Invitrogen) for 4 h at room temperature. All sections were counterstained with DAPI, mounted on slides, and coverslipped with Vectashield antifade mounting medium. The fluorescent images were acquired with a confocal laser scanning microscope (Nikon A1) and analyzed by using ImageJ and MetaMorph. Areas CA1 and CA3 and the dentate gyrus (DG) of hippocampus were independently outlined, and an intensity threshold was set to identify pixels that were GFAP-and vimentin-positive. The proportion of total pixels containing GFAP and vimentin immunoreactivity was then determined. NeuN-positive cells were counted, and the density of neurons in CA1, CA3, and DG was plotted and analyzed.
In Vivo Pharmacological Manipulation. Osmotic minipumps (model 1002; Alzet; flow rate, 0.25 μL/h; 2-wk duration) were filled with the NMDA receptor (NMDAR) antagonist D-(-)-2-amino-5-phosphonopentanoate [D-AP5; 5 mM in artificial cerebrospinal fluid (ACSF); Tocris] or vehicle (ACSF for a group of control mice), secured with the flow moderator, and primed overnight in 0.9% saline solution at 37°C before to be connected to the brain cannula (Alzet Brain Infusion Kit 3) by flexible catheter tubing. Two days after SE, mice were implanted with EEG as described earlier, and the brain cannula was stereotaxically placed into the right lateral ventricle (anteroposterior, −0.2 mm; mediolateral, −1.0 mm; dorsoventral, −2.2 mm). Animals were allowed to recover for 3 d. Osmotic minipumps were externalized, placed in a sealed conic tube of 1 mL filled with 0.9% saline solution, and maintained at 37°C with a iBlock Mini Dry Bath (Midsci) placed out of the cage. The catheter tubing was filled with D-AP5 (5 mM in ACSF; Tocris) or vehicle (ACSF for a group of control mice). A small air bubble was inserted into the catheter tubing during its connection with the pump to monitor the flow rate estimated at 0.25 μL/h in our conditions. The flexible catheter tubing was carefully aligned and attached to the EEG cable. The presence of a swivel (Pinnacle Technology) prevented the torsion of tubing and cable.
Slice Preparation. Coronal cortical-hippocampal slices (310-400 μm) were obtained from dnSNARE and WT mice at postnatal days 21 to 30. At birth, WT and dnSNARE mice that were to be used for brain slice studies were fed a doxycycline-free diet to allow transgene expression in the dnSNARE mice. Mice were anesthetized with isoflurane, and, after cervical dislocation, the brain was rapidly removed and put in ice-cold artificial ACSF containing the following (in mM): 120 NaCl, 3.2 KCl, 1 NaH 2 PO 4 , 26 NaHCO 3 , 1 MgCl 2 , 2 CaCl 2 and 10 glucose, pH 7.4 (with O 2 95%, CO 2 5%). After removal of the cerebellum, the brain was glued and coronal cortical-hippocampal slices were cut by using a Vibratome (VT1200S; Leica). Before recording, slices were incubated at 35°C for a recovery period of 1 h. After recovery, slices were placed in a submerged recording chamber (31°C; Warner Instruments) and continuously perfused (2 mL/min) with oxygenated ACSF.
Extracellular Recordings. Coronal cortical-hippocampal slices (400 μm) were visualized with a 16× objective in an upright Nikon Eclipse FN1 microscope. Glass electrodes (3-4 MΩ) for extracellular recording were filled with ACSF. Electrophysiological signals were amplified and filtered at 0.1 Hz and 1 kHz by a Multiclamp 700B amplifier (Axon Instruments), digitized at 5 kHz with Digidata 1322A (Axon Instruments), and stored in a personal computer with Clampex 9.2 (Axon Instruments). Epileptiform activity was generated with a proconvulsant ACSF containing 0 Mg 2+ to relieve the blockade of NMDA receptors and the GABA A receptor antagonist picrotoxin (100 μM; Sigma), and recorded in the CA1 pyramidal cells layer. Epileptiform events were detected with Clampfit 9.2 (Axon Instruments) and verified visually.
Patch-Clamp Recordings. CA1 pyramidal neurons from coronal cortical-hippocampal slices (310 μm) were visually identified with a 16× objective and 2× magnification in an upright Nikon Eclipse FN1 microscope by using IR-differential interference contrast. Whole-cell patch-clamp recordings were performed in current-and voltage-clamp modes by using a Multiclamp 700B amplifier (Axon Instruments). Data were filtered at 1 kHz and sampled at 5 kHz with Digidata 1322A interface and pClamp software (Axon Instruments).
For the AMPA/NMDA ratio measurements, a glass pipette (3-4 MΩ) was filled with the following internal solution (in mM): 120 Cs-MeSO 3 , 20 CsCl, 0.2 EGTA, Na-phosphocreatine 10, 5 QX-314, 4 Mg-ATP, 0.2 Na 3 -GTP, and 10 Hepes, pH 7.3 with CsOH. Biocytin (2 mg/mL; Sigma) was added to the internal solution in some experiments. Biocytin was allowed to passively diffuse into the cell for at least 10 min. Synaptic AMPA and NMDA currents were evoked by electrostimulation of the Schaffer collateral pathway at 0.033 Hz with a bipolar extracellular electrode (FHC) placed 100 to 200 μM apart from the recorded cell. Picrotoxin (100 μM; Sigma) was always added to the ACSF while measuring AMPA/NMDA ratio. After a stable synaptic current was obtained, AMPA currents were first recorded at −70 mV, then the AMPA receptor antagonist 2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide (10 μM; Tocris) was added to the ACSF, and finally the NMDA current was measured at +40 mV. The NMDAR antagonist D-AP5 (50 μM; Tocris) was added to the perfusion system at the end of the recording to confirm the nature of the evoked synaptic current. During AMPA/NMDA ratio measurements, a high-Mg 2+ and -Ca 2+ (4 mM of MgCl 2 and CaCl 2 ) ACSF was always used to increase membrane stability in the presence of picrotoxin. AMPA and NMDA currents were analyzed with Clampfit 9.2 (Axon Instruments). In some experiments, spontaneous excitatory postsynaptic currents (EPSCs; sEPSCs) were recorded at -70 mV before recording evoked AMPA and NMDA currents and analyzed using Minianalysis 6.0 software (Synaptosoft).
To measure the AMPA and NMDA components of miniature EPSCs (mEPSCs), cells were recorded at holding potential −70 mV in ACSF containing 0 Mg 2+ and 1 μM TTX (Tocris). Internal solution contained the following (in mM): 145 K-gluconate, 2 MgCl 2 , 5 EGTA, 2 Na 2 -ATP, 0.2 Na 3 -GTP, and 10 Hepes, pH 7.2 with KOH. Analysis of mEPSCs was performed by using Minianalysis 6.0 software (Synaptosoft). Events were detected automatically by using a threshold of 15 pA and verified visually. The average mEPSC waveform of each cell was aligned at their half-maximal rise time. The peak of an average mEPSC was taken as the AMPA peak. NMDA current amplitude was measured 20 ms after the AMPA peak. Before recording mixed AMPA and NMDA mEPSCs, cells were recorded in normal ACSF containing 1 mM Mg 2+ and a series of constant current pulses (from −300 to +300 pA for 300 ms with 20-pA increments, at 1-s intervals) was used to characterize their intrinsic membrane properties and excitability. Intrinsic membrane properties of CA1 pyramidal cells were not altered in dnSNARE mice (n = 15 cells from five animals) compared with WT mice (n = 11 cells from three animals). No difference was found in their resting membrane potential (WT, −74.00 ± 0.55 mV, vs. −72.46 ± 1.34 mV in dnSNARE; Student t test, P > 0.05) and membrane input resistance (WT, 146.94 ± 11.59 MΩ, vs. 154.16 ± 8.53 MΩ in dnSNARE; Student t test, P > 0.05). We also observed no difference in their excitability and the amplitude of evoked action potentials measured at rheobase (WT, 88.36 ± 2.28 mV, vs. 83.06 ± 2.80 mV in dnSNARE; Student t test, P > 0.05). Junction potentials were determined to allow correction of membrane potential values.
Glutamate and D-Serine Biosensor Recordings. Biosensor microelectrodes (Sarissa Biomedical) coated with an enzymatic matrix surrounding a platinum electrode (50-μm diameter) were polarized to +500 mV (vs. Ag/AgCl reference). Electrochemical detection occurred via amperometric measurement of hydrogen peroxide produced by the degradation reaction mediated by the enzymes included in the matrix. The current generated was proportional to the concentration of the analyte of interest. Glutamate release was measured by using a glutamate sensor, comprising glutamate oxidase and using a null sensor (possessing only the polymeric coat without enzymes), as background signals. Signals from the null sensor were subtracted from the signals generated by the glutamate sensor to give a measure of net glutamate concentrations. D-Serine release was measured by using a D-serine sensor, comprising D-amino acid oxidase and using a null sensor, as background. The principles and operation of glutamate and D-serine sensors have been previously described (4) (5) (6) (7) .
Pairs of sensors (glutamate/null or D-serine/null; 150-200 μm apart) were inserted sequentially into stratum radiatum of area CA1 of cortical-hippocampal slices (400 μm) continuously perfused (2 mL/min) with oxygenated ACSF at 31°C. Experiments commenced 30 min after the slices recover and the sensor signal asymptotes to a baseline level. Experiments consisted of collecting 20 min of stable baseline, sensor withdrawal, and sensor calibration. Upon sensor withdrawal, the glutamate and D-serine signals decreased below the preceding baseline level recorded in the slices. Subtraction of the pre-and postwithdrawal signals was used as an indirect measure of glutamate or D-serine tone. Calibration was performed after each experiment by washing in 10 μM L-glutamate (Sigma) or D-serine (Sigma). The θ-burst stimulation (TBS) of the Schaffer collaterals was performed with a bipolar extracellular electrode (FHC) positioned in the stratum radiatum 150 to 200 μm from the glutamate sensor. The TBS protocol was conducted 20 min after a stable baseline signal and consisted of one single train of five θ-bursts (75-100 μA) at 100 Hz separated by 200 ms (8) . Measurements were taken at the peak amplitude of the response. Potentiostat-based recordings were made by using the ME200+ Duo-Stat (Sycopel International) and sampled at 10 kHz with Digidata 1322A interface and pClamp software (Axon Instruments). Analysis was performed with Clampfit 9.2 (Axon Instruments).
Statistical Analysis. The difference between several groups was analyzed by one-way ANOVA. Two-way ANOVA was used when more than two comparisons (with time and genotype) were made. Repeated-measures ANOVAs were used when multiple measurements were made over time in the same groups. ANOVA was followed by a Student-Newman-Keuls post hoc multiple comparisons test and Bonferroni test for all behavior experiments. Comparisons between two groups were conducted with the paired or unpaired Student t test or the nonparametric MannWhitney test as appropriate. Proportions were compared as appropriate with the Fisher exact test or χ 2 test. Cumulative probability plots were calculated, and a Kolmogorov-Smirnov test was used to determine statistical differences. Kaplan-Meier analysis was performed, and the log-rank test was used to determine statistical differences. (2) during four successive injections of low-dose pilocarpine (20 min apart) was similar between WT (n = 12) and dnSNARE mice (n = 10; ANOVA, P > 0.05). (B) The latency to onset of SE after the first injection of pilocarpine was comparable in WT mice (n = 12) and dnSNARE mice (n = 10; Student t test, P > 0.05). (C) The percentage of mice that developed and survived SE induced with multiple injections of low-dose pilocarpine was similar in WT (n = 71) and dnSNARE mice (n = 58; χ 2 test, P > 0.05). (D and E) EEG recordings before and during SE induced with a single high dose of pilocarpine were subjected to fast Fourier transformation, and the power in different frequency bands was analyzed in WT (D) and dnSNARE mice (E). Representative analyses Legend continued on following page of band power in the β-band are shown. The zero time point corresponds to the time of scopolamine injection 30 min before the pilocarpine injection. Asterisks mark isolated acute seizures before mice enter continuous SE. The horizontal dashed line indicates the death of the animal. (Inset) Traces represent EEG recordings 15 min before pilocarpine injection (1), during the occurrence of an acute seizure (2), and during continuous SE (3) in WT (D) and dnSNARE mice (E). (Scale bars: 400 μA and 10 s.) (F) As a measure for the severity of acute seizures, the percentage change of power during acute seizures in different frequency bands was calculated relative to the power of the basal EEG recorded before pilocarpine injection. No differences were observed between WT (n = 9) and dnSNARE mice (n = 7; ANOVA, P > 0.05). (G) Similarly, the percentage change in EEG power during continuous SE was not different between WT and dnSNARE mice (n = 10 per genotype; ANOVA, P > 0.05). (H) Average latency to onset of acute seizure after the single injection of high-dose pilocarpine in WT (n = 9) and dnSNARE mice (n = 7; Mann-Whitney test, P > 0.05). (I) Average number of acute seizures occurring between the time of the single injection of high-dose pilocarpine and the beginning of SE in WT (n = 9) and dnSNARE mice (n = 7; Mann-Whitney test, P > 0.05). (J) Average duration of acute seizures occurring after the single injection of high-dose pilocarpine in WT (n = 9) and dnSNARE mice (n = 7; Student t test, P > 0.05). (K) Average latency of SE induced with the single injection of high-dose pilocarpine in WT and dnSNARE mice (n = 10 per genotype; Mann-Whitney test, P > 0.05). Fig. S2 . Normalized EEG spectral power in SE mice during an SRS (Left) and control no-SE mice (Right; 3-min recording). Power spectra were similar in WT and dnSNARE mice during the two different conditions (n = 5 per genotype; ANOVA, P > 0.05). average duration of seizures for each 1-mo block after SE in WT (n = 4-6) and dnSNARE mice (n = 6-8). Note that no difference was found in the seizure duration over time between genotypes (ANOVA, P > 0.05). (D) Average number of interictal spikes per day in seven WT (Upper) and eight dnSNARE mice (Lower) after SE. Horizontal dashed lines represent the maximum number of interictal spikes reached at day 144 after SE in WT mice. Note the reduced interictal spikes frequency in dnSNARE mice (Lower) compared with WT mice (Upper; ANOVA: genotype, P = 0.02; time, P < 0.001; genotype × time interaction, P = 0.960; post hoc test, *P < 0.05, **P < 0.01, and ***P < 0.001). Representative hippocampal sections from control no-SE and SE-experienced WT and dnSNARE mice stained with an antibody directed against the neuron-specific epitope NeuN 8 mo after pilocarpine treatment. A pronounced neuronal cell loss in areas CA1 (A, arrowheads) and CA3 (B, arrowheads) was detected in WT and dnSNARE mice that developed SE. Average neuronal density in CA1 (A) and CA3 (B) are presented under each corresponding section (WT no-SE, n = 3 animals; WT SE, n = 7 animals; dnSNARE no-SE, n = 5 animals; dnSNARE SE, n = 4 animals; ANOVA followed by post hoc test, *P < 0.05, **P < 0.01, and ***P < 0.001; ns, nonsignificant). (C and D) Same hippocampal sections as in A and B but stained with an antibody directed against the astrocyte-specific epitope GFAP. GFAP expression was increased in areas CA1 (C) and CA3 (D) in WT mice that entered SE but not in dnSNARE mice. Average GFAP area in CA1 (C) and CA3 (D) are presented under each corresponding section (ANOVA followed by post hoc test, *P < 0.05 and **P < 0.01; ns, nonsignificant). (Scale bars: 100 μm.) Fig. S6 . Vimentin staining in WT and dnSNARE mice after pilocarpine treatment. (A-C) Representative hippocampal sections from WT and dnSNARE mice that entered or did not enter SE stained with an antibody directed against the astrocyte-specific epitope vimentin 8 mo after pilocarpine treatment. Note the increased expression of vimentin in areas CA1 (A) and CA3 (B) and in the hilus of the DG (C) in WT mice that entered SE but not in dnSNARE mice. Average vimentin area in CA1 (A), CA3 (B), and hilus of the DG (C) are presented under each corresponding section (WT no-SE, n = 11 animals; WT SE, n = 11 animals; dnSNARE no-SE, n = 9 animals; dnSNARE SE, n = 7 animals; ANOVA followed by post hoc test, *P < 0.05, **P < 0.01, and ***P < 0.001; ns, nonsignificant). (Scale bars: 100 μm.) 
